EGFR and breast carcinoma: showed that EVs engineered to express EGFR and CD3 antibodies (termed “SMART‐Exos”) could induce cross‐linking of T cells and EGFR‐expressing breast cancer cells, thus eliciting potent antitumor immunity.[230]